Walleye Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$187K Sell
300
-200
-40% -$136K ﹤0.01% 3550
2026
Q1
$386K Sell
500
-11,900
-96% -$9.11M ﹤0.01% 2865
2025
Q4
$9.57M Buy
12,400
+6,900
+125% +$4.69M 0.03% 688
2025
Q3
$3.09M Sell
5,500
-5,200
-49% -$2.94M 0.01% 1251
2025
Q2
$5.62M Buy
10,700
+5,100
+91% +$2.85M 0.02% 809
2025
Q1
$3.55M Sell
5,600
-8,900
-61% -$6.12M 0.02% 1009
2024
Q4
$10.3M Buy
14,500
+3,800
+36% +$3.19M 0.03% 612
2024
Q3
$11.2M Sell
10,700
-4,500
-30% -$5.01M 0.02% 626
2024
Q2
$16M Sell
15,200
-4,600
-23% -$4.46M 0.03% 475
2024
Q1
$19.1M Buy
19,800
+10,600
+115% +$10.1M 0.03% 438
2023
Q4
$8.08M Sell
9,200
-3,500
-28% -$2.88M 0.02% 798
2023
Q3
$10.5M Buy
12,700
+11,700
+1,170% +$9.2M 0.03% 547
2023
Q2
$719K Sell
1,000
-900
-47% -$694K ﹤0.01% 2144
2023
Q1
$1.56M Buy
1,900
+1,600
+533% +$1.21M 0.02% 865
2022
Q4
$216K Sell
300
-1,100
-79% -$812K ﹤0.01% 1986
2022
Q3
$964K Buy
+1,400
New +$881K 0.02% 1004
2020
Q2
Sell
-400
Closed -$195K 906
2020
Q1
$195K Sell
400
-6,500
-94% -$2.68M 0.04% 448
2019
Q4
$2.59M Sell
6,900
-4,700
-41% -$1.58M 0.17% 147
2019
Q3
$3.22M Buy
11,600
+10,400
+867% +$3.08M 0.19% 118
2019
Q2
$376K Sell
1,200
-1,100
-48% -$366K 0.04% 636
2019
Q1
$944K Buy
+2,300
New +$947K 0.16% 185

Other funds holding REGN

Walleye Capital's REGN Position: Q2 2026 in Review

Walleye Capital increased its Regeneron Pharmaceuticals (REGN) stake by 462% in Q2 2026, buying an estimated $12.6M and bringing the position to 22,596 shares worth $14.1M. The position accounts for 0.05% of the portfolio, ranked #358.

Walleye Capital first reported a position in REGN in Q1 2019 and has held it in 20 quarters since. The position peaked at $49.2M in Q3 2025. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Walleye Capital held 22,596 shares of Regeneron Pharmaceuticals worth $14.1M as of Q2 2026.
  • Walleye Capital bought 18,574 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $12.6M.
  • Regeneron Pharmaceuticals made up 0.05% of Walleye Capital's portfolio in Q2 2026, its #358 holding.
  • Walleye Capital first reported a position in Regeneron Pharmaceuticals in Q1 2019 and has held it in 20 quarters since.
  • Walleye Capital's Regeneron Pharmaceuticals position peaked at $49.2M in Q3 2025.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.